Top Markets
Coin of the day
Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO
Rang in Aktien #6395
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Aktienkurs
$32.88
Marktkapitalisierung
$2.08B
Veränderung (1 Tag)
-0.48%
Veränderung (1 Jahr)
96.77%
Land
US
Handel Zenas BioPharma, Inc. (ZBIO)

Kategorie

Kursverlauf für Zenas BioPharma, Inc. (ZBIO)
Höchster Schlusskurs: $31.75 am 2026-08-01

Niedrigster Schlusskurs: $17.96 am 2024-09-01
Kursverlauf der Aktie von Zenas BioPharma, Inc. von 2024 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -33.58%
2025 294.97%
2024 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$548.36 40.94%
US
$1.06K 49.46%
NL
$122.63 -12.65%
AU
$140.81 461.00%
US
$765.25 7.19%
CH